Medtronic Plc Hits 52-Week Low at USD 78.29 Amid Market Decline

Medtronic Plc, a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 78.29 as of May 4, 2026. This decline marks a significant downturn for the stock, which has experienced a 1-year performance drop of 5.82%, contrasting sharply with the S&P 500's impressive gain of 26.63% during the same period. The company, with a market capitalization of USD 113,290 million, maintains a price-to-earnings (P/E) ratio of 20.00. Medtronic's dividend yield stands at 3.20%, reflecting its commitment to returning value to shareholders. The firm also boasts a low debt-to-equity ratio of 0.43, indicating a conservative approach to leverage. Despite the recent price decline, Medtronic has shown resilience in its operational metrics. The company reported a record operating cash flow of USD 7,146 million and a return on capital employed (ROCE) of 9.72% in its latest financial results. Additionally, institutional holdings remain robust at 86.93%, suggesting a strong foundation of support from sophisticated investors.